Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 275Carcinoma, Non-Small-Cell Lung 226Prostatic Neoplasms 182Neoplasms 174Multiple Myeloma 138Lung Neoplasms 137Neoplasm Metastasis 102Colorectal Neoplasms 101Melanoma 87Ovarian Neoplasms 80Pancreatic Neoplasms 74Leukemia, Myeloid, Acute 74Lymphoma 69Carcinoma, Renal Cell 65Leukemia, Lymphocytic, Chronic, B-Cell 64Brain Neoplasms 63Lymphoma, Non-Hodgkin 62Squamous Cell Carcinoma of Head and Neck 61Urinary Bladder Neoplasms 57Recurrence 56Hematologic Neoplasms 56Carcinoma, Hepatocellular 54Head and Neck Neoplasms 53Triple Negative Breast Neoplasms 52Glioblastoma 49Lymphoma, Follicular 48Endometrial Neoplasms 47Uterine Cervical Neoplasms 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Stomach Neoplasms 44

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pathologic Processes × 90 days × Clear all
NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡